Industry Best Practices for Novel Biotherapeutic Entities

How a Unified Data Model and Data Integrity Help Making Better Decisions

Biologic therapeutics are becoming more sophisticated, and pharmaceutical organizations are actively adopting the benefits that bi- and multispecific antibodies and antibody-drug conjugates offer. However, many informatics systems have not kept up with these advances, hampering the ability for researchers to effectively design these next-generation treatments.

This white paper explores best practices industry leaders are following to improve their R&D IT infrastructure and how these forward-thinking approaches can help you take your organization to the next level.